The Lavipharm Group’s total earnings before interest, taxes, depreciation, and amortization (EBITDA) from continuing operations for the first quarter of 2026 increased by 11%, reaching €3.13 million compared to €2.82 million during the corresponding period of the previous year.
Total earnings before interest, taxes, depreciation, and amortization (EBITDA) from the Group’s continuing and discontinued operations decreased by 16.9% due to the fact that in the first quarter of 2025, the Group had recognized a non-recurring gain of €973,000 from the sale of the pharmacy network.
It should be noted that the first quarter of 2026, like the first quarter of 2025, was burdened by a non-cash (accounting) recognition of the valuation of stock award and stock option plans attributable to the specific period, amounting to €215,000 for the current period, while for 2025 it was €239,000.
Consolidated sales from continuing operations before rebates and clawbacks amounted to €16.59 million in the first quarter of 2026, compared to €14.71 million in the corresponding period last year, representing an increase of 12.8%.
Gross profit for the first quarter of 2026 amounted to €6.58 million, compared to €6.03 million in the corresponding period of 2025, representing an increase of 9.1%.
Net profit before taxes from continuing operations amounted to €1.41 million, compared to €1.1 million in the corresponding period last year, representing an increase of 28.6%.
Total net profit after taxes amounted to €0.82 million, compared to €1.63 million in the corresponding period last year, a decrease of 49.8%.
As mentioned above, this decrease is attributable to the recognition of extraordinary income during the first quarter of 2025. The Lavipharm Group’s net debt as of March 31, 2026, stood at €24.74 million.
Regarding sales, sales of prescription drugs in the domestic market increased by 32.2%. Sales of over-the-counter (OTC) drugs decreased by 0.9%.
The Group’s exports, which amounted to €4.03 million compared to €4.72 million in the corresponding period last year, decreased by 14.6% a situation attributed to the delay in obtaining export licenses by customers, affecting sales of €1.1 million
It should be noted that, based on orders, the Group’s export activity for the year 2026 is expected to increase compared to 2025, while this estimate does not include sales resulting from the acquisition of the DUROGESIC®️ trademark rights.